SCHEMBL20122880

SCHEMBL20122880

Cc1nccc2c3cc(Cl)cc(-c4cnc(N(C)C)nc4)c3n(CC3CC3)c12

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
CRHR1 P34998 1/20 0.35
HASPIN Q8TF76 3/20 0.34
DYRK2 Q92630 1/20 0.34
DYRK1A Q13627 3/20 0.33
HTR2A P28223 1/20 0.33
HTR2C P28335 1/20 0.33
ALOX5 P09917 1/20 0.33
BRD4 O60885 2/20 0.33
BRD2 P25440 1/20 0.33
BRD3 Q15059 1/20 0.33
BRDT Q58F21 1/20 0.33
GRIN1 Q05586 3/20 0.32
GRIN2B Q13224 3/20 0.32
AXL P30530 1/20 0.32
TYRO3 Q06418 1/20 0.32
MERTK Q12866 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30664235 1.00 HDAC1 (0.35) HDAC1HDAC6CRHR1HASPINDYRK2
SCHEMBL20122937 0.88 BRD4 (0.37) HDAC1HDAC6CRHR1HASPINDYRK2
SCHEMBL30664292 0.88 BRD4 (0.37) HDAC1HDAC6CRHR1HASPINDYRK2
SCHEMBL20122759 0.83 DYRK1A (0.38) HDAC1HDAC6CRHR1HASPINDYRK2
SCHEMBL20122939 0.83 PIK3CA (0.38) HDAC1HDAC6CRHR1DYRK1AACHE
SCHEMBL30664227 0.82 DYRK1A (0.45) HDAC1HDAC6HASPINDYRK2DYRK1A
SCHEMBL20122960 0.82 DYRK1A (0.45) HDAC1HDAC6HASPINDYRK2DYRK1A
SCHEMBL20122737 0.82 RET (0.40) HDAC1HDAC6CRHR1
SCHEMBL22474564 0.81 CRHR1 (0.37) HDAC1HDAC6CRHR1HASPINDYRK2
SCHEMBL30664216 0.81 CRHR1 (0.37) HDAC1HDAC6CRHR1HASPINDYRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 HDAC1 3426/4885HDAC6 2798/4885CRHR1 908/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 HDAC1 3426/4885HDAC6 2798/4885CRHR1 908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.